Moderna Inc MRNA shares are trading higher during Monday’s pre-market session as investors focus shifts to an emerging global health concern, a hantavirus outbreak, that has highlighted the company's specialized research pipeline.

Inovio Pharmaceuticals and Novavax stocks pare back earlier gains as the rally loses enthusiasm.

(Reuters) -Moderna posted a smaller-than-expected quarterly loss and reduced its annual operating expenses outlook by $700 million on Thursday, helped by lower production costs and a cutback in research and development. In the third quarter, the COVID ...

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no. 1 on TIME's 2026 list of the World's Most Impactful Companies. The recognition highlights

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 run for the mRNA pioneer.

March 4 (Reuters) - Moderna shares rose ⁠9% ⁠on Wednesday after it settled ⁠a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing it to focus on its ‌pipeline. Analysts noted ...

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial stages, with potential public health benefits but years from availability.

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.